{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-011518","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2022-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.743839+00:00","generated_at":"2026-06-25T02:24:11.293071+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Exa-cel shows 95% TDT transfusion-free; CTX130 achieves 70% ORR in T-cell lymphoma","bullets":["42 of 44 TDT patients transfusion-free; all 31 SCD patients free of VOCs; follow-up up to 37.2 months.","Exa-cel primary endpoints amended: TDT target Hb ≥9 g/dL without transfusions; SCD target no severe VOCs.","Pediatric exa-cel studies CLIMB-141/151 now enrolling patients ages 5-11 with TDT or SCD.","CTX130 at DL3+: ORR 70% (30% CR) in PTCL/CTCL; 90% DCR; responses across all disease compartments.","CTX130 well tolerated: no DLTs, no GvHD, all CRS/ICANS grade 1-2; no treatment-related deaths."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-011518","json":"https://secwatch.observer/filing/0000950170-22-011518.json","markdown":"https://secwatch.observer/filing/0000950170-22-011518.md","text":"https://secwatch.observer/filing/0000950170-22-011518.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017022011518/0000950170-22-011518-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017022011518/crsp-20220611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T02:24:11.293071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}